PharmAust continues to tick off the milestones at its ongoing Phase I clinical trials for its anti-cancer drug Monepantel in dogs with the escalation study showing no adverse safety issues. Beagles treated with up to 10 Monepantel tablets displayed no adverse effects or signs of toxicity after being monitored over three days. The company will now start dosing tests to determine how best to maintain long term monepantel blood levels.
Related Data & Insights
-
-
Rank Company Revenue th PharmAust $842k 202 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX